{"id":"lopinavir-ritonavir-2-nrtis","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Abdominal pain"},{"rate":"20-40","effect":"Lipid abnormalities (elevated cholesterol/triglycerides)"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":"5-15","effect":"Hyperglycemia"},{"rate":"variable","effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lopinavir is a protease inhibitor that blocks the HIV protease enzyme, preventing the cleavage of viral polyproteins necessary for infectious particle formation. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing lopinavir plasma concentrations. The two NRTIs work synergistically by inhibiting reverse transcriptase, blocking conversion of viral RNA to DNA and preventing integration into the host genome.","oneSentence":"Lopinavir/ritonavir inhibits HIV protease to prevent viral maturation, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block viral RNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:25.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02140255","phase":"PHASE1, PHASE2","title":"Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-23","conditions":"HIV Infection","enrollment":1120},{"nctId":"NCT00866021","phase":"PHASE4","title":"Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-02","conditions":"HIV/HCV Co-infection, HIV Infections","enrollment":68},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT02227238","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-11","conditions":"HIV Infections","enrollment":627},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT01172535","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-11","conditions":"HIV","enrollment":97},{"nctId":"NCT00050895","phase":"PHASE3","title":"Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":775},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT00621166","phase":"PHASE2","title":"Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-06","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT00627055","phase":"PHASE4","title":"Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-05","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120},{"nctId":"NCT00089505","phase":"PHASE3","title":"NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2006-11","conditions":"HIV Infections","enrollment":745},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT02513147","phase":"PHASE4","title":"HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-06","conditions":"HIV-1","enrollment":44},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT00159224","phase":"PHASE4","title":"Induction-maintenance of Lopinavir/r in HIV-infected Subjects","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2005-04","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT01192035","phase":"PHASE4","title":"PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-05","conditions":"HIV-1","enrollment":400},{"nctId":"NCT00771498","phase":"PHASE4","title":"An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2008-11","conditions":"HIV Infection, Tuberculosis","enrollment":30},{"nctId":"NCT01307124","phase":"PHASE3","title":"Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-03","conditions":"HIV-infected Children","enrollment":199},{"nctId":"NCT00075907","phase":"PHASE3","title":"Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT01445223","phase":"PHASE4","title":"A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2004-04","conditions":"HIV","enrollment":242},{"nctId":"NCT00135395","phase":"PHASE3","title":"A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-05","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00004581","phase":"PHASE3","title":"A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment","status":"COMPLETED","sponsor":"Abbott","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00437476","phase":"PHASE3","title":"Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2007-02","conditions":"HIV Infections, Hepatitis C","enrollment":60},{"nctId":"NCT00052117","phase":"PHASE2","title":"Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"HIV Infections","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lopinavir/Ritonavir + 2 NRTIs","genericName":"Lopinavir/Ritonavir + 2 NRTIs","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lopinavir/ritonavir inhibits HIV protease to prevent viral maturation, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block viral RNA replication. Used for HIV-1 infection (treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}